Legal & General Group
KNSA icon

Legal & General Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Legal & General Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Sell
24,602
-3,964
-14% -$176K ﹤0.01% 2089
2025
Q4 		$1.18M Sell
28,566
-2,292
-7% -$91.9K ﹤0.01% 2163
2025
Q3 		$1.2M Hold
30,858
– – ﹤0.01% 2189
2025
Q2 		$854K Sell
30,858
-9,071
-23% -$231K ﹤0.01% 2282
2025
Q1 		$887K Sell
39,929
-1,338
-3% -$27.5K ﹤0.01% 2227
2024
Q4 		$816K Sell
41,267
-4,137
-9% -$94.4K ﹤0.01% 2305
2024
Q3 		$1.13M Buy
45,404
+1,502
+3% +$36.6K ﹤0.01% 2187
2024
Q2 		$820K Buy
43,902
+17,907
+69% +$335K ﹤0.01% 2261
2024
Q1 		$513K Buy
25,995
+927
+4% +$18.1K ﹤0.01% 2416
2023
Q4 		$440K Buy
25,068
+944
+4% +$15.5K ﹤0.01% 2510
2023
Q3 		$419K Buy
24,124
+55
+0.2% +$927 ﹤0.01% 2500
2023
Q2 		$339K Buy
24,069
+11,644
+94% +$156K ﹤0.01% 2582
2023
Q1 		$134K Buy
12,425
+713
+6% +$9.39K ﹤0.01% 2715
2022
Q4 		$175K Buy
11,712
+850
+8% +$12.4K ﹤0.01% 2664
2022
Q3 		$139K Buy
10,862
+148
+1% +$1.69K ﹤0.01% 2730
2022
Q2 		$103K Buy
10,714
+2,162
+25% +$20.2K ﹤0.01% 2850
2022
Q1 		$85K Hold
8,552
– – ﹤0.01% 2904
2021
Q4 		$101K Hold
8,552
– – ﹤0.01% 2906
2021
Q3 		$97K Buy
8,552
+4,732
+124% +$61.6K ﹤0.01% 2854
2021
Q2 		$53K Sell
3,820
-601
-14% -$9.13K ﹤0.01% 2929
2021
Q1 		$82K Buy
4,421
+130
+3% +$2.66K ﹤0.01% 2670
2020
Q4 		$76K Hold
4,291
– – ﹤0.01% 2659
2020
Q3 		$66K Buy
4,291
+29
+0.7% +$544 ﹤0.01% 2598
2020
Q2 		$108K Buy
4,262
+1,985
+87% +$41.5K ﹤0.01% 2504
2020
Q1 		$29K Sell
2,277
-815
-26% -$12.8K ﹤0.01% 2774
2019
Q4 		$34K Buy
3,092
+537
+21% +$4.67K ﹤0.01% 2992
2019
Q3 		$22K Hold
2,555
– – ﹤0.01% 3104
2019
Q2 		$35K Buy
2,555
+565
+28% +$8.77K ﹤0.01% 2938
2019
Q1 		$36K Buy
1,990
+1,010
+103% +$19.5K ﹤0.01% 2839
2018
Q4 		$28K Hold
980
– – ﹤0.01% 2937
2018
Q3 		$25K Buy
+980
New +$19.1K ﹤0.01% 3118

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Legal & General Group's KNSA Position: Q1 2026 in Review

Legal & General Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 14% in Q1 2026, selling an estimated $176K and leaving 24,602 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Legal & General Group first reported a position in KNSA in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.2M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Legal & General Group held 24,602 shares of Kiniksa Pharmaceuticals worth $1.18M as of Q1 2026.
  • Legal & General Group sold 3,964 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $176K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2089 holding.
  • Legal & General Group first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Legal & General Group's Kiniksa Pharmaceuticals position peaked at $1.2M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.